Neurocrine Biosciences
NBIX
589 hedge funds and large institutions have $12.9B invested in Neurocrine Biosciences in 2024 Q1 according to their latest regulatory filings, with 90 funds opening new positions, 226 increasing their positions, 210 reducing their positions, and 48 closing their positions.
88% more first-time investments, than exits
New positions opened: 90 | Existing positions closed: 48
43% more call options, than puts
Call options by funds: $88M | Put options by funds: $61.6M
6% more funds holding
Funds holding: 554 → 589 (+35)
8% more repeat investments, than reductions
Existing positions increased: 226 | Existing positions reduced: 210
3% more capital invested
Capital invested by funds: $12.5B → $12.9B (+$396M)
2.56% less ownership
Funds ownership: 96.57% → 94.01% (-2.6%)
25% less funds holding in top 10
Funds holding in top 10: 12 → 9 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$99.6M |
| 2 |
JP Morgan Chase
New York
|
+$76.4M |
| 3 |
PA
Perceptive Advisors
New York
|
+$72.9M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$63.3M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$353M |
| 2 |
Los Angeles Capital Management
Los Angeles,
California
|
-$91.9M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
-$75.8M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$75.7M |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$51.2M |
NBIX Hedge Fund Activity: Q1 2024 in Review
589 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q1 2024, worth a combined $12.9B — up 3.2% from $12.5B a quarter earlier.
Buyers outnumbered sellers: 90 funds opened new NBIX positions and 48 closed out — a net gain of 42 holders — while 226 added to existing stakes and 210 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $99.6M. The largest seller was Morgan Stanley, cutting an estimated $353M.
- 589 institutional investors held Neurocrine Biosciences (NBIX) as of Q1 2024, up from 554 in Q4 2023.
- Funds reported $12.9B of Neurocrine Biosciences stock for Q1 2024, up 3.2% quarter-over-quarter.
- 90 funds opened new Neurocrine Biosciences positions in Q1 2024 and 48 closed out, a net change of +42 holders.
- The largest Neurocrine Biosciences buyer in Q1 2024 was Citadel Advisors, an estimated $99.6M added.
- The largest Neurocrine Biosciences seller in Q1 2024 was Morgan Stanley, an estimated $353M sold.
Based on aggregated 13F filings for Q1 2024.